Payment overview · 2025
General Payments
$3,850.57
256 reported records · 35 companies
Healthcare provider profile · identity verified
Lawrence S Bluth, M.D
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · HARTFORD, CT · NPI 1699785469
Verified facts
What the public records show
CMS Open Payments records show Lawrence S Bluth, M.D received $3,850.57 in general payments during 2025 across 256 reported records.
PFIZER INC. accounted for 12.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nourianz, Nurtec Odt.
KYOWA KIRIN, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NOURIANZ as an associated drug or biological on 307 records involving 305 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Nourianz by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $490.23 | 12.7% | 43 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $369.91 | 9.6% | 32 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $352.51 | 9.2% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $336.93 | 8.8% | 32 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $278.76 | 7.2% | 20 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $228.66 | 5.9% | 21 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $151.06 | 3.9% | 9 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $150.83 | 3.9% | 14 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $149.15 | 3.9% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $126.69 | 3.3% | 6 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $119.78 | 3.1% | 10 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $98.06 | 2.5% | 4 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $83.84 | 2.2% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $74.09 | 1.9% | 4 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $73.53 | 1.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $64.80 | 1.7% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $64.08 | 1.7% | 3 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $59.08 | 1.5% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $53.46 | 1.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $52.13 | 1.4% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $51.33 | 1.3% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $49.00 | 1.3% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $48.94 | 1.3% | 3 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $46.22 | 1.2% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.76 | 1.2% | 5 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $37.07 | 1.0% | 2 | 2025 |
| Kedrion Biopharma, Inc. | Unresolved — no canonical attribution shown | $34.16 | 0.9% | 2 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $26.09 | 0.7% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $22.68 | 0.6% | 1 | 2025 |
| Invivyd Inc | Unresolved — no canonical attribution shown | $21.35 | 0.6% | 1 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $20.36 | 0.5% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $19.29 | 0.5% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $18.62 | 0.5% | 1 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.37 | 0.5% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $15.75 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,850.57 | 256 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $425.38 | 38 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $369.91 | 32 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $352.51 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $264.31 | 24 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $251.32 | 21 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $249.47 | 22 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $210.15 | 14 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $151.06 | 9 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $150.83 | 14 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $149.15 | 6 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | Octapharma USA, Inc., PFIZER INC. | $146.88 | 7 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $126.69 | 6 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $119.78 | 10 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $83.84 | 4 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $83.84 | 4 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $74.09 | 4 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $73.53 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $64.80 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $64.08 | 3 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $59.08 | 2 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $53.46 | 2 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $49.00 | 2 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $48.94 | 3 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $48.82 | 3 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $46.22 | 2 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $45.95 | 4 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $44.76 | 5 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $41.54 | 3 | 2025 |
Source payment records
|
|||||
| Albuked Normalized: albuked |
Biological | Kedrion Biopharma, Inc. | $34.16 | 2 | 2025 |
Source payment records
|
|||||
| GAMMAKED Normalized: gammaked |
Biological | Kedrion Biopharma, Inc. | $34.16 | 2 | 2025 |
Source payment records
|
|||||
| KEDRAB Normalized: kedrab |
Biological | Kedrion Biopharma, Inc. | $34.16 | 2 | 2025 |
Source payment records
|
|||||
| KOATE Normalized: koate |
Biological | Kedrion Biopharma, Inc. | $34.16 | 2 | 2025 |
Source payment records
|
|||||
| RhoGAM Ultra-Filtered PLUS Normalized: rhogam ultra filtered plus |
Biological | Kedrion Biopharma, Inc. | $34.16 | 2 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $32.26 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $22.68 | 1 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $22.66 | 2 | 2025 |
Source payment records
|
|||||
| PEMGARDA Normalized: pemgarda |
Biological | Invivyd Inc | $21.35 | 1 | 2025 |
Source payment records
|
|||||
| FIRDAPSE Normalized: firdapse |
Drug | CATALYST PHARMACEUTICALS, INC. | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $19.29 | 1 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| NOURIANZ Normalized: nourianz |
Drug | KYOWA KIRIN, INC. | $15.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NOURIANZ nourianz |
2025 | Nourianz | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| KYOWA KIRIN, INC. Exact reporting entity; no affiliate inference |
2025 | NOURIANZ open payments reported associated product |
CMS Open Payments — General Payments 307 supporting records · 305 recipient NPIs · example record 1222071383 |
Nourianz · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 467 | 126 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 417 | 98 |
| Levetiracetam | Levetiracetam | 321 | 65 |
| Duloxetine Hcl | Duloxetine Hcl | 180 | 54 |
| Primidone | Primidone | 127 | 28 |
| Lamotrigine | Lamotrigine | 83 | 17 |
| Propranolol Hcl | Propranolol Hcl | 82 | 21 |
| Nortriptyline Hcl | Nortriptyline Hcl | 74 | 25 |
| Topiramate | Topiramate | 62 | 17 |
| Donepezil Hcl | Donepezil Hcl | 59 | 15 |
| Rasagiline Mesylate | Rasagiline Mesylate | 43 | 13 |
| Divalproex Sodium | Divalproex Sodium | 41 | suppressed |
| Carbamazepine | Carbamazepine | 40 | suppressed |
| Tegretol Xr | Carbamazepine | 39 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 36 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 36 | suppressed |
| Carbamazepine Er | Carbamazepine | 35 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 26 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 24 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 24 | suppressed |
| Neupro | Rotigotine | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | suppressed |
| Azathioprine | Azathioprine | 20 | suppressed |
| Lamotrigine Er | Lamotrigine | 20 | suppressed |
| Levetiracetam Er | Levetiracetam | 20 | suppressed |
| Nourianz | Istradefylline | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 17 | suppressed |
| Phenobarbital | Phenobarbital | 16 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 14 | suppressed |
| Depakote Er | Divalproex Sodium | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 12 | suppressed |
| Aubagio | Teriflunomide | 12 | suppressed |
| Kesimpta Pen | Ofatumumab | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Teriflunomide | Teriflunomide | 12 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,850.57 · 256 records | PFIZER INC. | Albuked, BRIUMVI, Bafiertam, Briviact, CREXONT, FIRDAPSE, GAMMAKED, GOMEKLI, Gamunex-C, Gocovri, HYQVIA, KEDRAB, KESIMPTA, KEVEYIS, KISUNLA, KOATE, Leqembi, NOURIANZ, NUPLAZID, NURTEC ODT, OCTAGAM IMMUNE GLOBULIN (HUMAN), Ocrevus Zunovo, PANZYGA, PEMGARDA, PONVORY, QULIPTA, Qelbree, Radicava, RhoGAM Ultra-Filtered PLUS, Rystiggo, SKYCLARYS, Symbravo, Tascenso ODT, UBRELVY, ULTOMIRIS, UPLIZNA, VYALEV, VYEPTI, VYVGART HYTRULO, WAINUA, ZAVZPRET, Zilbrysq | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nourianz play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with KYOWA KIRIN, INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error